… drug discovery programs that have brought to market a large and growing number of
direct-acting antiretroviral drugs with various targets and mechanisms of action. It rapidly became …

The advent of direct-acting antivirals (DAAs) has brought about a sudden renaissance in the
treatment of chronic hepatitis C virus (HCV) infection with SVR rates now routinely >90%. …

… The development of antiviral drugs is a very complex process. Currently, around 50 drugs
have been approved for human use against viruses such as HSV, HIV-1, the cytomegalo virus, …

… HCV therapy has been revolutionised recently by the approval of two direct-acting antiviral
agents (DAA) against the NS3/4A serine protease for use in genotype 1 HCV, the ketoamide …

Treatment of hepatitis C virus (HCV) infection has progressed considerably with the approval
of interferon-free, direct-acting antiviral (DAA)-based combination therapies. Although most …

… These drugs, boceprevir and telaprevir, received regulatory approval in 2011 and are the
first direct-acting antiviral agents (DAAs) that selectively target HCV. During 2012, at least 30 …

… The development of new molecules called direct-acting antivirals (DAA) is ongoing (3).
The … Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. …

… Directly acting antivirals for the treatment of chronic hepatitis C: unresolved topics from
registration trials. Dig Liver Dis 2012; doi: 10.1016/j.dld.2012.05.002. 50. Ciesek S, von Hahn T, …

The major targets for direct-acting antivirals (DAAs) are the NS3/4A protease, the NS5A
protein, and the NS5B polymerase. The latter enzyme offers several target sites: the catalytic …

… With the advances in the science of HCV infection, the first part of the 21st century has seen
the development and early introduction of a number of direct-acting antiviral (DAA) drugs. …